
Please try another search
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test kits and analyzers. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization, and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Radiation Therapy Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive source, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. In addition, the company provides irradiation service for sterilization; and research, development, production, and sales of irradiation modified materials. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
Name | Age | Since | Title |
---|---|---|---|
Zhonglin Liu | 55 | 2021 | Chairman of the Board of Supervisors |
Chuang Lu | 46 | 2021 | Independent Non-Executive Director |
Guoping Zhang | 53 | 2019 | Supervisor |
Nanfei Zhao | 45 | 2021 | Supervisor |
Jinyu Chang | 53 | 2019 | Non Executive Director |
Qihui Peng | 31 | 2022 | Employee Representative Supervisor |
Jingshan Chen | 55 | 2021 | Independent Non-Executive Director |
Fuxin Ma | 33 | 2022 | Employee Representative Supervisor |
Chiu Kwok Poon | 63 | 2023 | Independent Non-Executive Director |
Yingying Huo | 42 | 2024 | Executive Director |
Jianmin Ding | 52 | 2023 | Non-Executive Director |
Rui An | 49 | 2024 | Independent Non-Executive Director |
Junqi Zhang | 53 | 2023 | GM & Executive Director |
Xiaoyu Ma | 44 | 2025 | Executive Director |
Yafei Xiao | - | 2025 | Chairman |
Zan Chen | 56 | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review